Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

This study is testing whether rezvilutamide, a hormone-blocking medication, can delay or prevent prostate cancer from coming back in men whose PSA levels are rising after prostate removal surgery — a situation called biochemical recurrence. **You may be eligible if...** - You are a male, 40 or older - You have a confirmed diagnosis of prostate adenocarcinoma - Your PSA level was below 0.1 ng/mL for at least 6 months after your prostatectomy - Your PSA has now risen above 0.2 ng/mL on two separate tests taken at least 2 weeks apart - There is no visible sign of cancer returning locally or spreading elsewhere - Your lymph nodes were negative (or unable to be assessed) at surgery **You may NOT be eligible if...** - Your cancer has spread to other parts of the body - Your PSA did not drop low enough after surgery - You have already received hormonal or radiation therapy for recurrence Talk to your doctor to see if this trial is right for you.